Recent news on Copegus

Pegasys Study Authors Conclude that Patients Successfully Treated ...  -  May 21, 2007
PharmaLive.com (press release),PEGASYS, in combination with COPEGUS, are indicated for the treatment of adults with chronic hepatitis C who have compensated liver disease and have not

Treatment Optimisation With PEGASYS Plus COPEGUS Offers Patients ...  -  Apr 12, 2007
FinanzNachrichten.de,Patients with genotype 1 hepatitis C (HCV) who clear the virus within a month of starting treatment with PEGASYS (peginterferon alfa-2a (40KD)) plus COPEGUS

Treatment Optimisation With PEGASYS Plus COPEGUS Offers Patients ...  -  Apr 12, 2007
Juraforum.de,The results of theanalysis showed that of those patients treated with PEGASYS 180 mcgweekly plus COPEGUS 1000-1200 mg daily:

APS: Treatment Optimisation With PEGASYS Plus COPEGUS Offers .....  -  Apr 12, 2007
ANP Pers Support,...clinical practice and are relevant to the patients we see every day. At the moment,. testing viral levels at 4 weeks of treatment is not standard practice.

Roche Driving PROGRESS in Treatment of Difficult-to-Cure Hepatitis ...  -  Apr 6, 2007
Drug Newswire (press release),PROGRESS will reveal whether induction dosing with PEGASYS in combination with a higher dose of COPEGUS offers these patients an improved chance of a cure.

PEGASYS(R) Gets European Approval for a Shorter Treatment Duration ...  -  Apr 6, 2007
Drug Newswire (press release),The EU approval is based on data from two pivotal clinical trials for PEGASYS plus COPEGUS.(1,2) Results from these trials show that among patients who

Sustained Response to Anti-Hepatitis C Virus Drugs Results in Cure ...  -  Apr 16, 2007
DG News...[Presentation title: Durable Sustained Virological Response After Treatment With Peginterferon a-2a (PEGYSUS) or in Combination With Ribavarin (COPEGUS):

Roche Posts Strong First Quarter Sales – Upgrade of Core Earnings ...  -  Apr 18, 2007
PharmaLive.com (press release),Roche’s hepatitis C franchise started the year well with sales growth of 15% for Pegasys, coupled with approval and launch of companion antiviral Copegus in

Analysis: Shorter therapy for hepatitis C?  -  Apr 16, 2007
Science Daily (press release)Roche makes pegylated interferon and ribavirin (Copegus) used in the trial. "These are still early results," he said. "We still need to run the data and see

Vertex Pharmaceuticals - Interim Results Presented at EASL from ...  -  Apr 16, 2007
Oxfordshire Bioscience Network (press release),...is being dosed as 750 mg every eight hours in combination with pegylated interferon alfa-2a (Pegasys®), both with and without ribavirin (Copegus®).

Analysis: Total hepatitis C cure possible  -  Apr 12, 2007
Science Daily (press release)...had a sustained virologic response when treated with pegylated interferon alfa-2a (PEGASYS) as monotherapy or in combination with ribavirin (COPEGUS).

EASL: Sustained Virologic Response Equals Cure for HCV Infection  -  Apr 12, 2007
MedPage Today,...virologic response after treatment with pegylated interferon alpha-2a (40 kD) (Pegasys) as monotherapy or in combination with ribavirin (Copegus).

Vertex Pharmaceuticals Announces New Data for Investigational HCV ...  -  Apr 11, 2007
PharmaLive.com (press release),...telaprevir is being dosed as 750 mg every 8 hours in combination with peginterferon alfa-2a (Pegasys(R)), both with and without ribavirin (Copegus(R)).

HIV and Hepatitis Co-Infections Challenging  -  Apr 6, 2007
MedPage Today,...of serum HCV RNA six months after the end of therapy, and the standard of care is pegylated interferon alfa (Pegasys) plus ribivarin (Copegus, Rebetol).

The NHI Drug Reimbursement Price Listing and Launch of the ...  -  Mar 16, 2007
PharmaLive.com (press release),Chairman and CEO: Franz B. Humer) for use in combination with Pegasys® for treating chronic hepatitis C. In Japan, Copegus® obtained approval for the

Roche Driving PROGRESS in Treatment of Difficult-to-Cure Hepatitis ...  -  Mar 14, 2007
news aktuell (Pressemitteilung),PROGRESS will reveal whether induction dosing with PEGASYS in combination with a higher dose of COPEGUS offers these patients an improved chance of a cure.

Roche Driving PROGRESS in Treatment of Hepatitis C  -  Mar 14, 2007
WebWire (press release),PEGASYS, in combination with COPEGUS (ribavirin), is indicated for the treatment of adults with chronic hepatitis C who have compensated liver disease and

Hep C Help  -  Mar 20, 2007
WFtv.com,Another drug called ribavirin (Copegus, Rebetol, Virazole) is often used along with interferon treatment. Ribavirin can help fight some viruses and is taken

- New International Trial Called PROGRESS Starts in 15 Countries  -  Mar 14, 2007
Juraforum.de,PROGRESSwill reveal whether induction dosing with PEGASYS in combination witha higher dose of COPEGUS offers these patients an improved chance ofa cure."

PEGASYS(R) Gets European Approval for a Shorter Treatment Duration ...  -  Mar 5, 2007
PR Newswire UK (press release),The EU approval is based on data from two pivotal clinical trials for PEGASYS plus COPEGUS.(1,2) Results from these trials show that among patients who

Roche Launches Hepatitis C Therapy in Japan  -  Mar 16, 2007
Reuters.uk,VX: Quote, Profile , Research) said on Friday it had launched Copegus as a combination therapy with Pegasys for patients with chronic hepatitis C in Japan.

Roche starts PROGRESS trial in Poland  -  Mar 21, 2007
Polish Market,The international study will evaluate the effect of Pegasys (peginterferon alfa-2a (40KD)) and Copegus (ribavirin) in hepatitis C patients who have a high

Copegus Approved In Japan As Combination Therapy With Pegasys For ...  -  Jan 29, 2007
Medical News Today (press release),Roche and Chugai announced today that the combination of Copegus (ribavirin) plus Pegasys (peginterferon alfa-2a (40KD)) has been approved in Japan

Hepatitis C Treatment Center  -  Feb 6, 2007
WebMDCOPEGUS is a medicine that works by slowing down the growth of the virus. COPEGUS should be taken with PEGASYS to fight the virus. Do not take COPEGUS by

Help for hepatitis C  -  Feb 8, 2007
News 8 Austin,Another drug called ribavirin (Copegus, Rebetol, Virazole) is often used along with interferon treatment. Ribavirin can help fight some viruses and is taken

Roche Posts Outstanding Results for 2006  -  Feb 7, 2007
PharmaLive.com (press release),The product remains the leading pegylated interferon treatment for chronic hepatitis C. Sales of Copegus (ribavirin) continued to decline overall due to

Pharma Sector: Few Newsmakers Of The Week - Pfizer, Merck, Coley ...  -  Jan 28, 2007
Trading Markets,...in getting its drug Pegasys approved for use in combination with antiviral ribavirin sold overseas as Copegus, for the treatment of chronic hepatitis C.

Vertex Pharmaceuticals Announces Results Of First Interim Safety ...  -  Dec 24, 2006
Medical News Today (press release),...mg every eight hours in combination with pegylated interferon alfa-2a (Pegasys(R)), both with and (in the PROVE 2 study) without ribavirin (Copegus(R)).

Vertex Pharmaceuticals Announces Results Of First Interim Safety ...  -  Dec 24, 2006
Medical News Today (press release),...mg every eight hours in combination with pegylated interferon alfa-2a (Pegasys(R)), both with and (in the PROVE 2 study) without ribavirin (Copegus(R)).

From the analyst's couch: Hepatitis C virus therapies  Sep 8, 2006
...alfa (PEG–IFN) — either 2a (Roche's Pegasys) or 2b (Schering-Plough's PEG-Intron) — and ribavirin (Rebetol (Schering-Plough), Copegus (Roche) and various ... -Nature.com (subscription)

Saving Your Liver  -  Nov 16, 2006
Forbes,Roche, which already sells pegylated interferon (Pegasys) and ribavirin (Copegus), announced in May that in a small early-stage trial its polymerase

African Americans Have Lower Response Rate To Standard Therapy For ...  Aug 16, 2006
Patients were treated for up to 48 weeks with peginterferon alfa-2a (Pegasys) 180 g/wk and ribavirin (Copegus) 1000 or 2000 mg/day based on body weight of 75 ... -eMaxHealth.com

Racial differences in hepatitis C viral responses  Aug 16, 2006
Study Design Patients were treated for up to 48 weeks with peginterferon alfa-2a (Pegasys.) 180 5g/wk and ribavirin (Copegus.) 1000 or 2000 mg/day based on ... -News-Medical.net

African Americans Have Lower Response Rate To Standard Therapy For  Aug 16, 2006
Patients were treated for up to 48 weeks with peginterferon alfa-2a (Pegasys®) 180 µg/wk and ribavirin (Copegus®) 1000 or 2000 mg/day based on body weight ... -WebWire

Operating Profit Falls For Roche Diagnostics  Jul 21, 2006
...in the first half-year, with the product maintaining its position as the world’s leading treatment for chronic hepatitis C. Copegus (ribavirin) sales ... -Inside INdiana Business

Hepatitis C ad blitz raises ethical qualms  Jul 18, 2006
...hepatitis C patients have been diagnosed but haven't been treated, and may not know about the company's current market-leading options: Pegasys and Copegus. ... -Miami Herald

Graphic hepatitis C ads raise ethical qualms  Jun 22, 2006
...t been treated, and may not know about the company's current market-leading options: Pegasys (interferon and an antiviral substance) and Copegus (an antiviral ... -Philadelphia Inquirer



Higher Dose COPEGUS(R) 400mg Tablets Approved in the Netherlands ...  Apr 23, 2006
Roche announced the start of the Mutual Recognition Procedure for a COPEGUS(R) (ribavirin) 400 mg tablet, following approval by the Dutch Medicines Evaluation ... - PR Newswire UK

Higher Dose Copegus (Ribarivin) 400mg Tablets Approved in the ...  Apr 24, 2006
BASEL, SWITZERLAND -- April 24, 2006 -- Roche announced the start of the Mutual Recognition Procedure for a Copegus(R) (ribavirin) 400 mg tablet, following ... - DG News

PEGASYS(R) ACCELERATE Trial Shows Six Months of Treatment Is ...  Apr 29, 2006
Patients were randomized to receive PEGASYS 180mcg once weekly plus COPEGUS(R) (ribavirin) 800mg daily for either 16 or 24 weeks, followed by 24 weeks of ... - PR Newswire

Roche's Innovative Oral Polymerase Inhibitor Shows Strong ...  May 1, 2006
...planned to study how well R1626 works in combination with Roche's current hepatitis drugs, PEGASYS(r) (peginterferon alfa-2a (40KD)) and COPEGUS(r) (ribavirin ... - PR Newswire UK

Roche Oral Drug Shows Promise in Hepatitis C  May 5, 2006
Further trials are planned to study how well R1626 works in combination with Pegasys (peginterferon alfa-2a) and Copegus (ribavirin). ... - International News Service

New Oral Polymerase Inhibitor Shows Promising Results in Chronic ...  Apr 29, 2006
Further trials are planned to study how well R1626 works in combination with PEGASYS® (peginterferon alfa-2a) and COPEGUS® (ribavirin). ... - Yahoo! News

Human Genome Updates Albuferon Data  May 1, 2006
...weeks of treatment. Ribavirin is the active ingredient in Roche Holding Group's Copegus hepatitis C treatment. Twelve weeks after ... - Houston Chronicle

New PEGASYS(R) Trial Shows Six Months of Treatment is Optimal for ...  May 1, 2006
In the trial, patients were randomised to receive PEGASYS(R) (peginterferon alfa-2a (40KD)) 180 mg once weekly plus COPEGUS(R) (ribavirin) 800 mg daily for ... - PR Newswire UK

(PRN) - Neuropharma Introduces in Clinical Trials its First ...  Apr 24, 2006
Services ... [+. PRN) - Higher Dose COPEGUS(R) 400mg Tablets Approved in the Netherlands as First Step to European Availability ... [+. ... - Bolsamania.com

(PRN) - BOURBON Orders 56 Platform Supply Vessels for its Offshore ...  Apr 23, 2006
...(PRN) - Higher Dose COPEGUS(R) 400mg Tablets Approved in the Netherlands as First Step to European Availability ... [+. PRN) - Gemplus ... - Bolsamania.com

Roche pharmaceuticals  Apr 23, 2006
...days to complete. COPEGUS. best chance for a cure," said William M. Burns, head of the pharmaceutical division at. Roche. "We look ... - ANP Pers Support

Roche Showed Continued Strong Sales Growth in the First Quarter ...  Apr 26, 2006
...of care. As anticipated, Copegus sales saw a marked decline, mainly due to the emergence of generic competition in the US. The HIV ... - PharmaLive.com





Novartis Licenses Hep C Drug  Mar 29, 2006
Roche makes a $1.38-billion combination treatment for the disease called Pegasys/Copegus. Schering-Plough makes Peg-Intron/Rebetol, worth $1.1 billion a year. ... - Red Herring

Hepatitis C Market: Plenty Of Potential, But Little Progress  Mar 31, 2006
One of those drugs is Ribavirin. It's an oral antiviral sold generically and as Copegus by Roche and Rebetol by Schering-Plough. (SGP). ... - Investor's Business Daily (subscription)

Human Genome Sciences: challenging the pegylated interferons  Mar 15, 2006
...combination therapy consisting of pegylated interferon (pegIFN) and ribavirin (RBV), marketed by Roche and Schering-Plough as Pegasys/Copegus and PegIntron ... - Pharmaceutical Business Review

Roche 2005: Record Sales and Operating Profit  Feb 1, 2006
A solid double-digit gain was recorded for combined sales of Valcyte and Cymevene. Combined sales of Pegasys and Copegus showed strong growth in 2005. ... - PharmaLive.com,

Vertex Successfully Completes Key Studies with VX-950 to Prepare ...  Feb 7, 2006
...mg every eight hours (q8h) for 28 days in combination with standard doses of pegylated interferon alfa-2a (Pegasys(R); peg-IFN) and ribavirin (Copegus(R); RBV ... - PharmaLive.com,

Vertex Reports Data On HCV Protease Inhibitor, Earnings  Feb 7, 2006
...eight hours in combination with standard doses of pegylated interferon alfa-2a (Pegasys, from F. Hoffmann-La Roche Ltd.) and ribavirin (Copegus, also from Roche ... - BioWorld Online (subscription)

First-Time Generic Approvals: Copegus, Tegretol, Roxicodone  Jan 24, 2006
...of ribavirin tablets (made by Three Rivers Pharmaceuticals LLC, Zydus Pharmaceuticals USA Inc, and Teva Pharmaceuticals Inc; brand name Copegus, made by Roche ... - Medscape (subscription)

Vertex Successfully Completes Key Studies with VX-950 to Prepare ...  Feb 7, 2006
...mg every eight hours (q8h) for 28 days in combination with standard doses of pegylated interferon alfa-2a (Pegasys(R); peg-IFN) and ribavirin (Copegus(R); RBV ... - CNW Telbec (Communiqués de presse)

Roche 2005: Record Sales and Operating Profit  Feb 1, 2006
A solid double-digit gain was recorded for combined sales of Valcyte and Cymevene. Combined sales of Pegasys and Copegus showed strong growth in 2005. ... - PharmaLive.com

Increase ribavirin dose for better HCV treatment response in ...  Jan 18, 2006
...response to hepatitis C virus (HCV) treatment, individuals coinfected with HIV and HCV should increase their dose of ribavirin (Copegus / Rebetol / Virazole ... - Aidsmap

Fatigue may be misdiagnosed as depression during anti-HCV therapy ...  Jan 23, 2006
...growth factor supplementation) in individuals receiving pegylated interferon alfa-2b (Viraferon-Peg / Peg-Intron) and ribavirin (Copegus / Rebetol / Virazole). ... - Aidsmap

Zacks.com Announces That Vivian Lewis Highlights the Following ...  Jan 17, 2006
Shipment began of the AB-rated generic equivalent of Roche's Copegus (R), used in combination with peginterferon alfa-2a to treat adults with chronic hepatitis ... - Business Wire

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional